Early Feasibility Study of the Supira System in Patients Undergoing HRPCI

NAActive, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 4, 2024

Primary Completion Date

April 17, 2025

Study Completion Date

June 30, 2025

Conditions
Coronary Artery DiseaseHigh-risk Percutaneous Coronary InterventionInterventional Cardiology
Interventions
DEVICE

Supira System

The Supira System is a minimally invasive, miniaturized percutaneous ventricular assist device (pVAD) system that is intended to provide temporary (≤4 hours) hemodynamic support to patients undergoing a HRPCI procedure. The Catheter is inserted percutaneously via the femoral artery, across the aortic valve, and into the left ventricle under fluoroscopic guidance, with a portion remaining in the ascending aorta. The left ventricle is unloaded by pumping blood from the ventricle into the ascending aorta and systemic circulation.

Trial Locations (4)

10029

Mount Sinai, New York

10467

Montefiore Medical Center Cardiology Research, The Bronx

30309

Piedmont Heart Institute Cardiovascular Research, Atlanta

95817

University of California Davis (UC Davis) Medical Center, Sacramento

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Supira Medical

INDUSTRY

NCT06087575 - Early Feasibility Study of the Supira System in Patients Undergoing HRPCI | Biotech Hunter | Biotech Hunter